Piramal Enterprises Reports 20% Revenue Growth, DHFL Integration Boosts Financial Services Scale
Piramal Enterprises achieved 20% year-on-year revenue growth, reaching Rs. 3,816.00 crores. Financial Services segment saw 25% increase in gross income and 31% growth in loan book to Rs. 60,600.00 crores. Retail AUM quadrupled to Rs. 21,500.00 crores. DHFL merger expanded scale, yielding 11% with 4% spread. Pharma segment revenue grew 18%. Normalized net profit increased 14% to Rs. 888.00 crores. Company expects continued growth and plans to complete demerger in Q3 FY23.

*this image is generated using AI for illustrative purposes only.
Piramal Enterprises has reported a robust quarterly performance, showcasing significant growth across its key business segments. The company's strategic moves, including the DHFL merger, have contributed to its expanded scale and improved financial metrics.
Strong Revenue Growth
Piramal Enterprises delivered an impressive 20% year-on-year revenue growth, with total revenues reaching Rs. 3,816.00 crores. This growth was driven by strong performances in both the Financial Services and Pharma segments.
Financial Services Segment Performance
The Financial Services segment demonstrated remarkable progress:
- Gross income increased by 25%
- Overall loan book grew by 31% to Rs. 60,600.00 crores
- Retail Assets Under Management (AUM) quadrupled to Rs. 21,500.00 crores
- Retail share of AUM rose from 12% to 36%
DHFL Merger Impact
The approval of the DHFL merger has significantly expanded Piramal Enterprises' scale:
- The DHFL acquisition is yielding over 11% with borrowing costs at 7%, creating a 4% spread
- 3,000 DHFL employees were retained, and an additional 2,000 were hired
- Loan originations restarted at most branches
- Disbursements grew five-fold year-on-year to Rs. 739.00 crores
Pharma Segment Growth
The Pharma business also showed strong performance:
- Revenue growth of 18%
- Nine-month revenues reached Rs. 4,500.00 crores
- CDMO business faced execution challenges due to supply chain constraints and raw material availability
- CDMO order book grew by 32%
- The company expects near 20% growth for the overall Pharma business in FY22
Profitability and Future Outlook
- Normalized net profit grew by 14% to Rs. 888.00 crores
- The company is implementing a twin-engine strategy combining secured lending and embedded finance
- The demerger into separate entities is expected to complete in Q3 FY23
Piramal Enterprises' strong performance across its business segments, coupled with the successful integration of DHFL, positions the company for continued growth. The expansion in retail AUM and the robust performance of the Pharma segment demonstrate the company's ability to capitalize on diverse business opportunities.
Historical Stock Returns for Piramal Enterprises
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
+0.60% | -3.23% | -8.55% | +19.09% | +0.48% | +56.05% |